MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Aileron Therapeutics Long Term Debt Current 2011-2026 | ALRN
Annual Long Term Debt Current Aileron Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 48 K | 33 K | 93 K | - | 446 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 446 K | 33 K | 155 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.38 | -0.58 % | $ 367 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.72 | 3.24 % | $ 8.95 B |  Australia |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.6 | -2.29 % | $ 16.3 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
2 K | $ 6.31 | -1.79 % | $ 180 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Fulcrum Therapeutics
FULC
|
2.4 M | $ 7.79 | -0.51 % | $ 494 K | USA |
 |
Galectin Therapeutics
GALT
|
22 K | $ 2.22 | -13.28 % | $ 142 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Gilead Sciences
GILD
|
102 M | $ 138.97 | -0.83 % | $ 173 B | USA |
 |
Genmab A/S
GMAB
|
26 M | $ 27.51 | -0.86 % | $ 17.3 B |  Danmark |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Gossamer Bio
GOSS
|
938 K | $ 0.32 | -6.5 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
117 M | $ 8.03 | -2.43 % | $ 6.83 B |  Spain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
GT Biopharma
GTBP
|
58 K | $ 0.41 | -6.9 % | $ 2.26 M | USA |
 |
Halozyme Therapeutics
HALO
|
13.3 M | $ 63.53 | 0.71 % | $ 7.61 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
45 M | $ 89.39 | -2.07 % | $ 27.2 B | Germany |
 |
Coherus BioSciences
CHRS
|
1.83 M | $ 1.64 | -2.1 % | $ 192 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.07 M | $ 27.66 | -0.18 % | $ 1.59 B | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 319.97 | -3.14 % | $ 41.9 B | USA |
 |
iBio
IBIO
|
490 K | $ 2.11 | 3.69 % | $ 22.2 M | USA |
 |
ImmuCell Corporation
ICCC
|
85.5 K | $ 6.6 | -0.15 % | $ 59.6 M | USA |
 |
IDEAYA Biosciences
IDYA
|
339 K | $ 30.88 | -4.51 % | $ 2.73 B | USA |
 |
InflaRx N.V.
IFRX
|
257 K | $ 0.97 | 2.89 % | $ 152 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Immutep Limited
IMMP
|
205 K | $ 0.35 | -3.08 % | $ 1.08 B | Australia |
 |
Immuron Limited
IMRN
|
34.4 K | $ 0.82 | -0.12 % | $ 6.29 M | Australia |
 |
Immatics N.V.
IMTX
|
1.88 M | $ 10.24 | -0.73 % | $ 644 M | Germany |
 |
Incyte Corporation
INCY
|
5.7 M | $ 94.06 | -0.84 % | $ 18.4 B | USA |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |